Our infectious disease work, in partnership with the Bill & Melinda Gates Foundation has built strong capabilities where we are developing product candidates that target pathogens that are predominant in the developing world.
Our IntelliSelect® Transgenic platforms, which contain a human antibody repertoire, provide an important surrogate for assessing normal human immune responses to infection. This allows us to test the efficacy of research-stage vaccines and to identify therapeutic antibodies targeting pathogens. With the Bill & Melinda Gates Foundation and their partners we have active programmes in malaria, RSV, influenza, HIV, Bordetella pertussis and antimicrobial-resistant bacterial pathogens.
Alongside this work we are developing product candidates that target human viruses associated with transplantation and cancer.